Although inadequate treatment for malaria is not the sole contributor to splenomegaly persistence in this population, CDC has recommended that primaquine be prescribed to all refugees with splenomegaly arriving from a malaria-endemic region who are G6PD-negative, and clinical progression should be closely followed after treatment administration. This evidence concerns the gene G6PD and Splenomegaly.